© Midjourney x What’s up Doc
The tricolor group informed the ANSM of “The cessation of the marketing of cynomel (sodium liothyronine)”, treatment which concerns around 3,000 patients, “As of October 31, 2025”, According to a statement from the health agency, which has provided a replacement solution.
Asked about the reasons for this marketing judgment, the ANSM replied that he was following “A production stopping” of Cynomel, marketed only in France.
“In 2022, the company responsible for the production of cynomel for Sanofi announced its intention to stop this activity. A safety stock has been produced to anticipate production stopping. This stock will supply the French market until October 2025 ”, said Sanofi.
A new treatment will be imported as a replacement
“To ensure the continuity of treatment of patients”, The laboratory has undertaken to import alternative treatment into France, the Thybon 20 Henning (Liothyronine Chlorhydrate), authorized in Germany for more than 25 years, underlines the ANSM.
According to the press release, these imports will take effect as soon as the cynomel is stopped and will be followed by a marketing authorization request for Thybon, in order to “Ensure lasting access to this medication” et “To prevent patients with repeated drug changes”.
https://www.whatsupdoc-lemag.fr/article/levothyrox-nouveau-rebondissement-judiciaire-sur-lindemnisation-de-45-patients
“There will be no supply break between the end of Cynomel distribution and the start of the provision of Thybon”, Ensures the ANSM.
The two drugs have the same basic molecule (Lithyronine) but different excipients.
With AFP
